Tramadol Pretreatment Enhances Ketamine-Induced Antidepressant Effects and Increases Mammalian Target of Rapamycin in Rat Hippocampus and Prefrontal Cortex by Yang, Chun et al.
Hindawi Publishing Corporation
Journal of Biomedicine and Biotechnology
Volume 2012, Article ID 175619, 6 pages
doi:10.1155/2012/175619
Research Article
TramadolPretreatmentEnhancesKetamine-Induced
AntidepressantEffectsand IncreasesMammalian Targetof
Rapamycin in Rat HippocampusandPrefrontal Cortex
ChunYang,1 Wen-YuanLi,2 Hai-YinYu,3 Zhi-QinGao,3 Xiang-LiuLiu,1
Zhi-QiangZhou,1 andJian-JunYang1
1Department of Anesthesiology, School of Medicine, Jinling Hospital, Nanjing University, No. 305 East Zhongshan Road,
Jiangsu Nanjing 210002, China
2Department of Anesthesiology, Aﬃliated Drum-Tower Hospital of Medical College of Nanjing University,
No. 321 Zhongshan Road, Jiangsu Nanjing 210008, China
3The PLA 102nd Hospital and Mental Health Center of Military, No. 55 North Heping Road, Jiangsu Changzhou 213000, China
Correspondence should be addressed to Jian-Jun Yang, yjyangjj@126.com
Received 14 January 2012; Revised 6 February 2012; Accepted 8 February 2012
Academic Editor: Daniel T. Monaghan
Copyright © 2012 Chun Yang et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Several lines of evidence have demonstrated that acute administration of ketamine elicits fast-acting antidepressant eﬀects.
Moreover, tramadol also has potential antidepressant eﬀects. The aim of this study was to investigate the eﬀects of pretreatment
with tramadol on ketamine-induced antidepressant activity and was to determine the expression of mammalian target of
rapamycin(mTOR)inrathippocampusandprefrontalcortex.Ratswereintraperitoneallyadministratedwithketamineatthedose
of 10mg/kg or saline 1h before the second episode of the forced swimming test (FST). Tramadol or saline was intraperitoneally
pretreated 30min before the former administration of ketamine or saline. The locomotor activity and the immobility time of FST
were both measured. After that, rats were sacriﬁced to determine the expression of mTOR in hippocampus and prefrontal cortex.
Tramadol at the dose of 5mg/kg administrated alone did not elicit the antidepressant eﬀects. More importantly, pretreatment with
tramadolenhancedtheketamine-inducedantidepressanteﬀectsandupregulatedtheexpressionofmTORinrathippocampusand
prefrontal cortex. Pretreatment with tramadol enhances the ketamine-induced antidepressant eﬀe c t s ,w h i c hi sa s s o c i a t e dw i t ht h e
increased expression of mTOR in rat hippocampus and prefrontal cortex.
1.Introduction
Mountingstudieshavedemonstratedthatketamine,awidely
used anesthetic agent, has antidepressant eﬀects in animal
models or patients [1–4]. Compared with conventional
antidepressant agents, ketamine exerts fast-acting antide-
pressant eﬀects within 1-2h after administration. Moreover,
ketamine also has therapeutic eﬀects for patients with
treatment-resistant depression [1, 5–9].
Mammalian target of rapamycin (mTOR) is a serine/
threonine kinase that modulates the initiation of protein
translation, which controls new protein synthesis as required
for synaptogenesis [10]. Mounting studies have shown that
mTOR plays a critical role in the process of ketamine-
exerting antidepressant eﬀects [10, 11] .Ar e c e n ts t u d yh a s
indicated that ketamine’s antidepressant eﬀects are associ-
ated with the upregulation of mTOR in prefrontal cortex
[12], which is conﬁrmed by a subsequent case report with
an increase of mTOR in the peripheral blood in a depressed
patient [13]. Moreover, Jernigan et al. [14]h a v ed e t e c t e d
decreased mTOR expression in depressed patients’ brain in
the postmortem study. These ﬁndings indicate that mTOR
acts as a crticical role in the pathogenesis of depression.
On the other hand, tramadol is a widely used analgesic
agent, which exerts therapeutic eﬀects via activation of
opioid receptors and elevating the plasma levels of serotonin
and norepinephrine [15]. As we know, the most prescribed
conventional antidepressant agents produce their eﬃcacy
also through increasing the monoamine levels, which share2 Journal of Biomedicine and Biotechnology
the identical mechanisms as tramadol. From this point of
view, we thus suggested that tramadol also has potential to
exert antidepressant eﬀects.
However, there is no information available at present
regarding the eﬀects of pretreatment with tramadol on
the ketamine-induced antidepressant activity. Therefore, this
study aimed to evaluate the eﬀects of tramadol pretreat-
ment on ketamine-induced antidepressant activity and to
determine the expression of mTOR in rat hippocampus and
prefrontal cortex.
2.MaterialsandMethods
2.1. Animals. Eighty-six male Wistar rats weighing 180–
220g were purchased from Shanghai Animal Center, Shang-
hai, China. The rats were housed 5 per cage with food and
water available ad libitum and were maintained on a 12h
light/darkcycle(lightsonat7:00am).Animalswereinvolved
inthisexperimentinaccordancewiththeGuideforCareand
Use of Laboratory Animals of National Institutes of Health.
2.2. Drugs and Treatment. Ketamine was obtained from
Gutian Pharmaceutical Company (Fujian, China). Tramadol
waspurchasedfromGrunenthalGmbH(Germany).Oneday
before drug pretreatment, rats were involved in the FST for
15min as pretest session. At the day of drug pretreatment,
rats wereintraperitoneally injected with tramadol at the dose
of 5mg/kg or saline, respectively. Thirty minutes later, rats
were intraperitoneally injected with ketamine at the dose of
10mg/kg or saline 1h before the second episode of the FST,
respectively. Another 30min later, FST was conducted for
5min as test session, and the immobility time was recorded.
All the interventions were administrated in the same volume
of 1mL.
2.3. Open-Field Tests. Locomotor activity of rats was evalu-
ated by using open-ﬁeld tests, which were performed during
light phase of the light-dark cycle. The open-ﬁeld consisted
of an arena of 100 × 100cm square ﬂoor surrounded by
30cm high wall. The ﬂoor of the arena was divided into 25
equal squares. Thirty minutes later after the drug or saline
intervention, rats were placed in the center of the square,
andthenumbersofcrossingsandrearingsweresubsequently
recorded [16].
2.4. Forced Swimming Test (FST). The FST included two
separate exposures to a cylindrical tank with water in which
rats cannot touch the bottom of the tank. The volume of
the tank was 60cm tall, 30cm in diameter, and was ﬁlled
with water in a depth of 40cm. All the procedures were
conductedbetween9:00–15:00. Ratswereplacedinthewater
for 15min without any administration. Twenty-four hours
later, rats were treated as the ﬁrst episode lasting 5min,
and the immobility time of rats was recorded. Rats were
intraperitoneally administrated with intervents in the same
volume at 30min before the second episode of the FST. Each
rat was judged to be immobile when it ceased struggling
and remained ﬂoating motionless in the water, making only
those movements necessary to keep its head above water.
Immobility time was recorded by the same observer. Water
in the tank was changed after the test of every rat.
2.5. Western Blotting. Immediately after the FST, the rats
were sacriﬁced by decapitation, and the hippocampus and
prefrontal cortex were rapidly dissected out on an ice-cold
plate, frozen, and stored at −80◦C until used. Samples of
homogenates(15μgofprotein) weresubjectedtoSDS-PAGE
under reducing conditions. Proteins were transferred onto
PDVF membranes, and the stripped blots were kept blocking
solution for 1hr and incubated with the antiphospho mTOR
Ser 2448 (1:2000, Cell Signaling) directed against total levels
of the mTOR (1:2000, Cell Signaling) for loading control.
Densitometric analysis of immunoreactivity for each protein
was conducted using Image J software.
2.6. Statistical Analysis. Statistical analysis was performed
by Statistical Product for the Social Sciences (SPSS version
17.0).Dataareexpressedasmean ±standarddeviation(SD).
Comparisons were made by one-way analysis of variance
(ANOVA) and post hoc comparisons were performed by the
least signiﬁcant diﬀerence tests. Diﬀerences were considered
to be signiﬁcant at P<0.05.
3. Results
Diﬀerent doses of tramadol were intraperitoneally injected
to investigate its antidepressant eﬀects. Rats showed a
signiﬁcant decrease in the immobility time during the FST
after the administration of tramadol at the dose of 10mg/kg
(Figure 1, P<0.05). However, tramadol at the doses of 2.5
and5mg/kgbothdidnotelicitanychangesoftheimmobility
time as compared with saline-treated rats (Figure 1, P>
0.05).
Before the FST, open-ﬁeld test was required to test
whether locomotor activities were aﬀected in the experi-
mental rats. Compared with saline-treated rats, treatment
with ketamine at the dose of 10mg/kg did not induce
any signiﬁcant changes of crossings and rearings of rats
in the open-ﬁeld test (Figure 2(a), P>0.05). Moreover,
tramadol pretreatment also did not change the crossings and
rearings of ketamine-treated rats as compared with saline
(Figure 2(b), P>0.05).
Ketamine-treated rats showed a signiﬁcant decrease in
immobility time during the FST as compared with saline
(Figure 3, P<0.05), and pretreatment with tramadol at the
dose of 5mg/kg further decreased immobility time of rats in
the FST as compared with ketamine-treated alone (Figure 3,
P<0.05).
Compared with saline-treated rats, the administration of
ketamine at the dose of 10mg/kg signiﬁcantly increased the
levels of mTOR in rat hippocampus (Figure 4, P<0.05), and
pretreatment with tramadol at the dose of 5mg/kg increased
the levels of mTOR as compared with ketamine-treated rats
(Figure 4, P<0.05).
Compared with saline-treated rats, the administration
of ketamine at the dose of 10mg/kg signiﬁcantly increasedJournal of Biomedicine and Biotechnology 3
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Figure 1: Immobility time of rats (n = 10) during the FST after intraperitoneal injection of tramadol at diﬀerent doses. Tramadol
administered at the dose of 10mg/kg signiﬁcantly decreased the immobility time as compared to saline (∗P<0.05), while tramadol
administered at the doses of 2.5 and 5mg/kg both did not aﬀect the immobility time (P>0.05).
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Figure 2 :( a )T h es c o r e so fc r o s s i n g so fr a t s( n = 10) during open-ﬁeld tests. Ketamine administered at the dose of 10mg/kg did not aﬀect
the scores of crossings, and pretreatment with 5mg/kg tramadol did not aﬀe c ta n yc h a n g e so fs c o r e so fc r o s s i n g s( P>0.05). (b) The scores
of rearings of rats (n = 10) during open-ﬁeld tests. Ketamine administered at the dose of 10mg/kg did not aﬀect the scores of rearings, and
pretreatment with 5mg/kg tramadol did not aﬀect any changes of scores of rearings (P>0.05).
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Figure 3: The immobility time of rats (n = 10) during the FST after intraperitoneal injection of ketamine and pretreatment with tramadol.
Ketamine administered at the dose of 10mg/kg signiﬁcantly decreased the immobility time as compared with control (∗P<0.05), and
pretreatment with 5mg/kg tramadol signiﬁcantly decreased the immobility time as compared with ketamine administration (#P<0.05).4 Journal of Biomedicine and Biotechnology
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Figure 4: The expression of p-mTOR in rat hippocampus (n = 3). Ketamine administered at the 10mg/kg signiﬁcantly increased the
expression of p-mTOR in rat hippocampus as compared with control (∗P<0.05), and tramadol pretreated at the dose of 5mg/kg
signiﬁcantly increased the expression of p-mTOR as compared with ketamine administered alone (#P<0.05).
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Figure 5: The expression of p-mTOR in rat prefrontal cortex (n = 3). Ketamine administered at the 10mg/kg signiﬁcantly increased the
expression of p-mTOR in rat prefrontal cortex as compared with control (∗P<0.05), and tramadol pretreated at the dose of 5mg/kg
signiﬁcantly increased the expression of p-mTOR as compared with ketamine administered alone (#P<0.05).
the levels of mTOR in rat prefrontal cortex (Figure 5, P<
0.05),andpretreatmentwithtramadolatthedoseof5mg/kg
increased the levels of mTOR in rat prefrontal cortex as
compared with ketamine-treated rats (Figure 5, P<0.05).
4. Discussion
The FST is a widely used behavioral test in rodents, which
is sensitive and selective for clinically eﬀective antidepressant
agents [17]. In this study, the results showed that ketamine
signiﬁcantly decreased the immobility time of rats during
the FST, suggesting that ketamine has exact antidepressant
eﬀects. More importantly, this study demonstrated that
tramadol administrated alone at the dose of 10mg/kg could
elicit signiﬁcant decrease in immobility time of rats during
the FST, and our ﬁndings also showed that tramadol under
the dose of 10mg/kg did not induce a signiﬁcant change
of immobility time. Therefore, we administrated tramadolJournal of Biomedicine and Biotechnology 5
at the dose of 5mg/kg in this study to avoid its potential
antidepressant eﬀects. Interestingly, although administration
of tramadol at the dose of 5mg/kg could not elicit any
antidepressant eﬀects, pretreatment with it could enhance
ketamine-indued antidepressant eﬀects. However, the exact
mechanisms of pretreatment with tramadol-enhancing
ketamine-induced antidepressant eﬀects are unclear.
A previous study shows that ketamine suppresses the
serotonin transporter and norepinephrine transporter in
cultured human embryonic kidney 293 cells [18]. Moreover,
Reeves and Burke [19] demonstrated that the increase of
serotonin and norepinephrine neurotransmitter is the core
mechanism of tramadol exerting its eﬃcacy. Thus ketamine
and tramadol may have synergistic eﬀects to elevate the sero-
tonin and norepinephrine levels in central nervous system,
which then lead to the enhanced antidepressant eﬀects.
Wang et al. [20] have shown that propofol, an anesthetic
agent, administered alone does not elicit antidepressant
eﬀects, but may enhance ketamine-induced antidepressant
eﬀects. R´ eus et al. [21] have observed that the coadminis-
tration of ketamine and imipramine produces the enhanced
antidepressant eﬀects, and the authors attribute the underly-
ing mechanisms of enhanced ketamine-induced antidepres-
santeﬀectstotheincreasedexpressionofglutamate-α-amino
-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor-1
in rat hippocampus, cyclic adenosine monophosphate re-
sponse element-binding and brain-derived neurotrophic
factor protein levels, and protein kinase C and protein kinase
A phosphorylation in rat brain, respectively. Interestingly,
our study showed that pretreatment with tramadol-
enhancing ketamine-induced antidepressant eﬀects was
associated with the increased expression of mTOR in rat
hippocampus and prefrontal cortex.
As above mentioned, ketamine’s antidepressant eﬀects
aremainlyduetotheupregulationofmTORinratprefrontal
cortex, and the activation of mTOR can stimulate the synap-
togenesis [12]. The induction of mTOR signaling occurs
within 30min after ketamine administration [10]. Collec-
tively, these ﬁndings suggest that ketamine’s antidepressant
eﬀects are associated with mTOR-dependent synaptogenesis
in rat prefrontal cortex. Our ﬁndings exhibited an enhanced
expression of mTOR in rat hippocampus and prefrontal
cortex after pretreatment with tramadol. Until now, no data
has shown that tramadol has eﬀects on the expression of
mTOR or synaptogenesis. So we supposed that tramadol
has eﬀects on stimulation of synaptogenesis via activating
mTOR, which may contribute to the underlying mechanism
of tramadol-enhancing ketamine-induced antidepressant
eﬀects.
In Conclusion, Ketamine exerts exactly antidepressant
eﬀects in rats during the FST, and tramadol pretreatment
enhances its antidepressant eﬀects. The relevant mechanisms
are potentially ascribed to the activation of mTOR in rat hip-
pocampus and prefrontal cortex. However, we did not eval-
uate whether tramadol-pretreatment-enhancing ketamine-
induced antidepressant eﬀects are related to synaptogenesis
in rat hippocampus, and further studies are needed to
understand the exact relevant mechanisms.
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